Novadip Press Release
July 8, 2025

Novadip and Cliniques universitaires Saint-Luc report positive results for compassionate use of NVD003 on four pediatric patients

NVD003 is a bone grafting…
read more
Novadip Press Release
June 20, 2025

Novadip receives RMAT designation for NVD003, its regenerative treatment for congenital pseudarthosis of the tibia

Novadip is developing NVD003, an…
read more
Novadip Press Release
April 29, 2025

Novadip releases five-year follow-up results for NVD003, regenerative treatment for severe bone non-union of lower limb

No refractures were reported during…
read more
Novadip Press Release
April 24, 2025

Novadip reports key nonclinical and interim clinical data for NVDX3, its off-the-shelf allogeneic product, in spine fusion

Novadip reports key nonclinical and…
read more
Novadip Press Release
October 17, 2024

Novadip reports promising interim results from its first-in-human proof-of-concept trial with NVDX3, a new game changer in the bone field

At six months post-grafting surgery…
read more
Novadip Press Release
December 27, 2022

Novadip Biosciences SA Appoints Judy Ashworth, MD, as Chief Medical Officer

Mont Saint-Guibert, Belgium – December…
read more
Novadip Press Release
December 9, 2022

Novadip Biosciences SA Announces Positive Results from Phase 1/2 Clinical Trial in Patients with Severe Bone Non-Union of the Lower Limb Following Trauma

Study results demonstrate NVD-003 has…
read more
Novadip Press Release
November 4, 2022

Novadip Biosciences Raises Additional EUR 40 Million Bringing Total Company Funding to EUR 88 Million

Funding will support development of…
read more
Novadip Press Release
October 28, 2021

Novadip Biosciences announces EUR 19 million Series B financing backed by international investors

Novadip Biosciences announces EUR 19…
read more
Novadip Press Release
June 15, 2021

Novadip Biosciences reports positive data from phase I study of NVD-001 for spinal fusion

Novadip Biosciences reports positive data…
read more